Meeting Report: Third ESWI Science Policy Interface Roundtable, Bucharest (22 October 2026)
Consistent messaging, collaboration and a clear way forward needed to strengthen prevention in Romania
Adult Respiratory Vaccination Delivers Up to $12 in Societal Value for Every $1 Spent, Analysis Finds
Benefit-cost modeling estimated $22B annual spend produces $101B-$241B net benefits, preventing ~18,500 deaths and 300,000 hospitalizations in a single year.
Effectiveness of nirsevimab immunisation on invasive pneumococcal disease in children nationwide in France: an observational cohort study
These findings suggest an additional benefit of nirsevimab implementation beyond RSV disease prevention, but further studies are needed.
Article
Scientific Papers
Viral pneumonia in older adults: from immunosenescence and chronic disease to vaccine-modifiable risk
This narrative review examines viral pneumonia in older adults at the intersection of immunosenescence, frailty, multimorbidity and immune compromise.
#EURespiDay 2026 looks ahead to a Council Recommendation on respiratory virus immunisation for cardiovascular prevention
Organised by the Steering Group on Prevention of Respiratory Infections
Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season - COVID-19, RSV, Influenza
JAMA Special Communications - Three systematic reviews identify & summarise recent reporting on the effectiveness and safety of vaccines and influenza/RSV/Covid-19 epidemiology in the US.
WHO prequalifies multi-dose RSV vaccine vial, paving the way to protecting more infants globally
The WHO has prequalified the multi-dose vial presentation of the maternal respiratory syncytial virus (RSV) vaccine, RSVpreF (ABRYSVO®).
News
Reports
Partner Organisations
EHMA: Prepact - A Receptivity Assessment for HMPV and RSV Diagnosis in Older Adults
EMA White Paper assessing receptivity to improving testing and surveillance for RSV & HMPV across Europe, with a specific focus on older adults.